タイトル | Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir. |
---|
ジャーナル・号・ページ | Nat Commun, Vol. 14, Page 6463-6463, Year 2023 |
---|
掲載日 | 2023年2月19日 (構造データの登録日) |
---|
著者 | Jiang, X. / Su, H. / Shang, W. / Zhou, F. / Zhang, Y. / Zhao, W. / Zhang, Q. / Xie, H. / Jiang, L. / Nie, T. ...Jiang, X. / Su, H. / Shang, W. / Zhou, F. / Zhang, Y. / Zhao, W. / Zhang, Q. / Xie, H. / Jiang, L. / Nie, T. / Yang, F. / Xiong, M. / Huang, X. / Li, M. / Chen, P. / Peng, S. / Xiao, G. / Jiang, H. / Tang, R. / Zhang, L. / Shen, J. / Xu, Y. |
---|
リンク | Nat Commun / PubMed:37833261 |
---|
手法 | X線回折 |
---|
解像度 | 1.66 - 2.46 Å |
---|
構造データ | PDB-8ifp: SARS-CoV-2 3CL protease (3CLpro) in complex with compound 1 手法: X-RAY DIFFRACTION / 解像度: 1.78 Å PDB-8ifq: SARS-CoV-2 3CL protease (3CLpro) in complex with compound 2 手法: X-RAY DIFFRACTION / 解像度: 1.96 Å PDB-8ifr: SARS-CoV-2 3CL protease (3CLpro) in complex with compound 3 手法: X-RAY DIFFRACTION / 解像度: 1.66 Å PDB-8ifs: SARS-CoV-2 3CL protease (3CLpro) in complex with compound 7 手法: X-RAY DIFFRACTION / 解像度: 2.46 Å PDB-8ift: SARS-CoV-2 3CL protease (3CLpro) in complex with compound 10 手法: X-RAY DIFFRACTION / 解像度: 1.8 Å PDB-8igx: SARS-CoV-2 3CL protease (3CLpro) in complex with compound 9 (simnotrelvir, SIM0417, SSD8432) 手法: X-RAY DIFFRACTION / 解像度: 1.9 Å PDB-8igy: SARS-CoV-2 3CL protease (3CLpro) in complex with nirmatrelvir 手法: X-RAY DIFFRACTION / 解像度: 1.96 Å |
---|
化合物 | ChemComp-OZ6: (1R,2S,5S)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethyl-butanoyl]-6,6-dimethyl-N-[(2S)-1-oxidanylidene-3-[(3S)-2-oxidanylidenepyrrolidin-3-yl]propan-2-yl]-3-azabicyclo[3.1.0]hexane-2-carboxamide
ChemComp-I1Z: (1R,2S,5S)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-N-{(1Z,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
ChemComp-P0O: (1R,2S,5S)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethyl-butanoyl]-6,6-dimethyl-N-[(2S)-5-oxidanylidene-1-[(3S)-2-oxidanylidenepyrrolidin-3-yl]hex-3-en-2-yl]-3-azabicyclo[3.1.0]hexane-2-carboxamide
ChemComp-OZL: (8~{S})-7-[(2~{S})-2-(~{tert}-butylcarbamoylamino)-3,3-dimethyl-butanoyl]-~{N}-[(1~{S})-1-cyano-2-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]ethyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxamide
ChemComp-OZB: (8S)-N-[(1S)-1-cyano-2-[(3S)-2-oxidanylidenepyrrolidin-3-yl]ethyl]-7-[(2S)-2-[(1-fluoranylcyclopropyl)carbonylamino]-3,3-dimethyl-butanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxamide
ChemComp-PQL: (8~{S})-~{N}-[(1~{S})-1-cyano-2-[(3~{S})-2-oxidanylidenepyrrolidin-3-yl]ethyl]-7-[(2~{S})-3,3-dimethyl-2-[2,2,2-tris(fluoranyl)ethanoylamino]butanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxamide
ChemComp-4WI: (1R,2S,5S)-N-{(1E,2S)-1-imino-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}-6,6-dimethyl-3-[3-methyl-N-(trifluoroacetyl)-L-valyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide / 薬剤, 抗ウイルス剤, プロテアーゼ阻害剤*YM
|
---|
由来 | - severe acute respiratory syndrome coronavirus 2 (ウイルス)
|
---|
キーワード | VIRAL PROTEIN / Mpro / Viral protein-inhibitor complex / VIRAL PROTEIN/INHIBITOR |
---|